Document Classification

Section Type: RESULTS

Text: Median OS of ganitumab versus placebo in patients with higher levels of IGF-1, IGF-2, and IGFBP-3 was 16 versus 6. 8 months (HR, 0. 25 ; 95 % CI : 0. 09-0. 67), 16 versus 5. 9 months (HR, 0. 24 ; 95 % CI : 0. 09-0. 68), and 16 versus 6. 8 months (HR, 0. 28 ; 95 % CI : 0. 11-0. 73), and in patients with lower IGFBP-2 levels was 12. 7 versus 6. 6 months (HR, 0. 19 ; 95 % CI : 0. 07-0. 55).